Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
暂无分享,去创建一个
F. D. De Braud | G. delle Fave | M. Gion | L. Dogliotti | P. Tomassetti | M. Zatelli | E. D. degli Uberti | M. Ambrosio | M. Torta | A. Leon
[1] Judy L. Smith,et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas , 2002, Annals of Surgical Oncology.
[2] M. Falconi,et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. , 2005, Endocrine-related cancer.
[3] D. Santini,et al. Endocrine pancreatic tumors: factors correlated with survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] C. Herfarth,et al. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract , 1992, World Journal of Surgery.
[5] F. D. De Braud,et al. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. , 2005, The International journal of biological markers.
[6] G. Lucignani,et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. , 2004, The International journal of biological markers.
[7] G. Rindi,et al. Endocrine Tumors of the Gut and Pancreas Tumor Biology and Classification , 2004, Neuroendocrinology.
[8] G. Sassolas,et al. Interest of Chromogranin A for diagnosis and follow‐up of endocrine tumours , 2004, Clinical endocrinology.
[9] H. Ramstad,et al. Clinical significance of elevated serum chromogranin A levels , 2004, Scandinavian journal of gastroenterology.
[10] L. Gullo,et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study , 2003, American Journal of Gastroenterology.
[11] M. Stridsberg,et al. A comparison between three commercial kits for chromogranin A measurements. , 2003, The Journal of endocrinology.
[12] I. Modlin,et al. A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.
[13] T. Khashoggi. A single institution experience , 2003 .
[14] M. Arosio,et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. , 2003, European journal of endocrinology.
[15] J. C. Tony. The chromogranin-secretogranin family. , 2003, The New England journal of medicine.
[16] J. Sloan,et al. The spectrum of endogenous human chromogranin A‐derived peptides identified using a modified proteomic strategy , 2002, Proteomics.
[17] S. Lamberts,et al. Neuroendocrine Tumor Markers , 2001, Frontiers in Neuroendocrinology.
[18] M. Ferdeghini,et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours , 2001, British Journal of Cancer.
[19] E. Baudin,et al. Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma , 2001, British Journal of Cancer.
[20] L. Gullo,et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours , 2001, European journal of gastroenterology & hepatology.
[21] L. Dogliotti,et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] E. Baudin,et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] E. Seregni,et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] D. Pons-Anicet,et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245) , 1999, British Journal of Cancer.
[25] V. Vilgrain,et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area , 1998, Gut.
[26] R. Bouillon,et al. Chromogranin A: its clinical value as marker of neuroendocrine tumours , 1998, European journal of clinical investigation.
[27] M. Stridsberg,et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. , 1995, The Journal of endocrinology.
[28] M. P. Canale,et al. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. , 1994, The Journal of clinical endocrinology and metabolism.
[29] E. Wilander,et al. Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients , 1990, Journal of internal medicine.